Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissectionWerntz, Ryan P.a; Pearce, Shane M.b; Eggener, Scott E.aCurrent Opinion in Urology: September 2018 - Volume 28 - Issue 5 - p 461–468 doi: 10.1097/MOU.0000000000000530 TESTICULAR CANCER: Edited by Aditya Bagrodia and Peter Albers Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Examine and discuss indications, technique, and outcomes for robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer. Recent findings Open RPLND has been the longstanding standard of care for both primary and post chemotherapy RPLND. Recently, robotic RPLND has been an attractive option with the intent of reducing the morbidity associated with open surgery while providing identical oncologic efficacy. Naysayers of robotic RPLND suggest it is often inappropriately used as a staging procedure and consequently can compromise oncologic efficacy. Summary Robotic RPLND is being evaluated as a therapeutic equivalent to open RPLND. On the basis of limited published data with modest follow-up from experienced centers, robotic RPLND appears to provide effective staging and therapeutic data mirroring that of open surgery. aSection of Urology, Department of Surgery, The University of Chicago Medicine bInstitute of Urology, University of Southern California, Los Angeles, California, USA Correspondence to Ryan P. Werntz, MD, Section of Urology, Department of Surgery, The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 6038, Chicago, IL 60637, USA. E-mail: firstname.lastname@example.org Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.